Hyaluronic acid fillers with cohesive polydensified matrix for soft-tissue augmentation and rejuvenation: a literature review

Adri D Prasetyo1
Welf Prager2
Mark G Rubin3
Ernesto A Moretti4
Andreas Nikolis5

1Rejuva Skin & Beauty, Surabaya, Indonesia; 2Prager & Partner, Hamburg, Germany; 3University of California, San Diego, CA, USA; 4Gamma Health Group, Sanatorio Los Arroyos, Santa Fe, Republic of Argentina; 5Victoria Park Clinical Research Centre, Westmount, QC, Canada

Background: Cohesive monophasic polydensified fillers show unique viscoelastic properties and variable density of hyaluronic acid, allowing for a homogeneous tissue integration and distribution of the material.

Objective: The aim of this paper was to review the clinical data regarding the performance, tolerability, and safety of the Belotero® fillers for soft-tissue augmentation and rejuvenation.

Methods: A literature search was performed up until May 31, 2015 to identify all relevant articles on Belotero® fillers (Basic/Balance, Hydro, Soft, Intense, Volume) and equivalent products (Esthélis®, Mesolis®, Fortélis®, Modélis®).

Results: This comprehensive review included 26 papers. Findings from three randomized controlled trials showed a greater reduction in nasolabial fold severity with Belotero® Basic/Balance than with collagen (at 8, 12, 16, and 24 weeks, n=118) and Restylane® (at 4 weeks, n=40), and higher patient satisfaction with Belotero® Intense than with Perlane® (at 2 weeks, n=20). With Belotero® Basic/Balance, an improvement of at least 1 point on the severity scale can be expected in ~80% of patients 1–6 months after injection, with an effect still visible at 8–12 months. Positive findings were also reported with Belotero® Volume (no reduction in hyaluronic acid volume at 12 months, as demonstrated by magnetic resonance imaging), Soft (improvement in the esthetic outcomes when used in a sequential approach), and Hydro (improvement in skin appearance in all patients). The most common adverse effects were mild-to-moderate erythema, edema, and hematoma, most of which were temporary. There were no reports of Tyndall effect, nodules, granulomas, or tissue necrosis.

Conclusion: Clinical evidence indicates sustainable esthetic effects, good safety profile, and long-term tolerability of the Belotero® fillers, particularly Belotero® Basic/Balance and Intense.

Keywords: CPM®, dermal filler, facial lines, filling, nasolabial fold, wrinkle

Introduction

In recent years, injectable dermal fillers have challenged the use of more invasive esthetic surgical procedures.1–3 Based on a survey conducted by the International Society of Aesthetic Plastic Surgery, there were more than eleven million nonsurgical procedures performed worldwide in 2013, and more than three million involved resorbable fillers.4 Nonpermanent dermal fillers are mainly used for the filling of rhytides and folds, and the correction of soft-tissue loss caused by disease or age.5
They provide volume restoration, with minimal downtime, favorable safety profile, and rapid and reproducible results.6

The most commonly used dermal filler is hyaluronic acid (HA).7 According to the statistics of the American Society for Aesthetic Plastic Surgery, >1.6 million HA filler procedures were performed in 2014 in the US, making it the second most frequently used nonsurgical esthetic procedure after botulinum toxin.

HA, which is a naturally occurring biopolymer, is degraded by a family of enzymes called hyaluronidases.8 Various crosslinking techniques have been developed to prevent the rapid degradation of HA in the skin and provide long-term treatment effects.1,9,10 The crosslinking technology, the uniformity and size of the particles, and the HA concentration of the filler determine its viscoelastic properties, and therefore its clinical effect.5

The first HA dermal fillers on the market were non-cohesive biphasic fillers, characterized as crosslinked particles suspended in a non-crosslinked HA matrix acting as a lubricant.11,12 These products (eg, Restylane®, Q-Med AB, Uppsala, Sweden, a wholly owned subsidiary of Galderma, Fort Worth, TX, USA; HA concentration 20 mg/mL) are manufactured with non-animal-stabilized hyaluronic acid (NASHA®) technology.13 A large variety of HA dermal fillers have since been designed.

Monophasic monodensified fillers, in contrast to biphasic gels, do not undergo “sizing”, a process that breaks down the gel.14 As a result, they contain a single phase of HA with a single density.11 Different families of monophasic monodensified fillers exist depending on the manufacturing technology, such as the Hylacross® technology (eg, Juvéderm® Ultra, Allergan, Santa Barbara, CA, USA; HA concentration 24 mg/mL) or the Vycross® technology (eg, Juvéderm® Volbella, HA concentration 15 mg/mL).15 Cohesive monophasic polydensified gels (Belotero® range; Anteis S.A., Geneva, Switzerland, a wholly owned subsidiary of Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany) were more recently introduced. In contrast to monodensified fillers which are crosslinked once, polydensified fillers contain a single phase of HA that is crosslinked continuously.11 They are manufactured with the cohesive polydensified matrix (CPM®) technology, resulting in a gel with nonuniform crosslinking and molecular weight16 and a viscosity that is lower than that of other fillers (comparing fillers targeting the same indication).17 These properties allow for a more homogeneous intradermal distribution of the material.1,18

The Belotero® range of products offers different densities of HA (concentration ranging from 18 to 26 mg/mL) to suit different purposes regarding soft-tissue augmentation and rejuvenation. The first Belotero® dermal filler available on the market was Belotero® Basic, initially launched in Germany in 2005. The equivalent product Belotero® Balance was approved by the US Food and Drug Administration in 2011. The Belotero® range also includes Belotero® Hydro, Soft, Intense, and Volume.

Since their introduction, a large quantity of clinical data has been collected on the Belotero® dermal fillers. The objective of this paper was to review the clinical evidence regarding the performance, tolerability, and safety of the Belotero® dermal fillers for soft-tissue augmentation and rejuvenation.

Materials and methods
Clinical evidence was reviewed for the whole range of Belotero® dermal fillers, which are briefly described in Table 1.

The PubMed database was searched for all relevant articles up until May 31, 2015, using the following keywords: “Belotero”, “Esthélis/Esthélis” (both terms, if number of hits were different), “Fortélis/Fortelis”, “Modélis/Modelis”, “Mesolis”, “Merz”, “Anteis”, “hyaluronic”, “hyaluronate”, “cohesive polydensified matrix”, “CPM technology”, “polydense cohesive matrix”, and “monophasic polydensified”.

The literature search was performed by independent medical writers. Additional references were also retrieved after reading the initial references and review articles. Selected papers were published in peer-reviewed journals in one of the following languages: English, French, and German. Conference abstracts were not considered for review.

The study design, injection procedures and injected volume, population, and main assessments are described for each clinical study in Table 2. Performance assessment was based on quantitative scales, such as the Merz Aesthetics Scales or the Wrinkle Severity Rating Scale (WSRS), or more subjective scales (patient-reported assessment), which are briefly described in Table 3. Less frequently, performance was assessed using objective imaging techniques. Mean wrinkle depth was measured using a 3 dimensional technique called phase-shift rapid in vivo measurement of skin,9,19 referred to as skin topography or high-resolution profilometry.20 Magnetic resonance imaging (MRI) was used in patients with facial lipoatrophy to quantify the volume of HA, bound water content, skin thickness, and tissue vascularization.21 The integration of the filler in the tissue was assessed by ultrasonography,22–24 a technique also used to measure skin thickness.
Table 1  Key characteristics and indications of Belotero® dermal fillers and hyaluronic acid fillers used as comparators in split-face, randomized controlled trials

<table>
<thead>
<tr>
<th>Brand name</th>
<th>Type of filler, crosslinking technology, and HA concentration (C)</th>
<th>Indications and depth of injection</th>
<th>Countries with marketing authorization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Belotero® dermal fillers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Belotero® Hydro</td>
<td>Non-crosslinked product; also contains glycerol; C = 18 mg/mL</td>
<td>Improvement of skin hydration, radiance, and elasticity; to be injected into the superficial dermis</td>
<td>EU</td>
</tr>
<tr>
<td>Also: Mesolis® Plus (or +)</td>
<td></td>
<td></td>
<td>Canada</td>
</tr>
<tr>
<td>Belotero® Soft</td>
<td>Crosslinked product; cohesive (monophasic) polydensified filler, CPM® technology; C = 20 mg/mL</td>
<td>Correction of fine lines (eg, crow’s feet, perioral lines, fine forehead lines); also suitable for lip enhancement and correction of facial atrophic scars; to be injected into the superficial-to-mid dermis</td>
<td>EU</td>
</tr>
<tr>
<td>Also: Esthélis® Soft</td>
<td></td>
<td></td>
<td>Canada</td>
</tr>
<tr>
<td>Belotero® Basic/Balance</td>
<td>Crosslinked product; cohesive (monophasic) polydensified filler, CPM® technology; C = 22.5 mg/mL</td>
<td>Correction of moderate lines (eg, moderate nasolabial wrinkles, glabellar lines, moderate perioral wrinkles, lip contouring, philtrum); also suitable for lip enhancement and correction of facial atrophic scars; to be injected into the superficial-to-mid dermis</td>
<td>EU</td>
</tr>
<tr>
<td>Also: Esthélis® Basic/Balance</td>
<td></td>
<td></td>
<td>Canada</td>
</tr>
<tr>
<td>Belotero® Intense</td>
<td>Crosslinked product; cohesive (monophasic) polydensified filler, CPM® technology; C = 25.5 mg/mL</td>
<td>Correction of deeper lines (eg, severe NLF, lip volume, oral commissures, marionette folds); also suitable for correction of facial atrophic scars; to be injected into the deep dermis</td>
<td>EU</td>
</tr>
<tr>
<td>Also: Fortélis® Extra</td>
<td></td>
<td></td>
<td>Canada</td>
</tr>
<tr>
<td>Belotero® Volume</td>
<td>Crosslinked product; cohesive (monophasic) polydensified filler, CPM® technology; C = 26 mg/mL</td>
<td>Restoration of facial volumes (eg, cheeks, temples, facial volume loss); to be injected into the deep dermis, subcutaneously or on the upper periostea</td>
<td>EU</td>
</tr>
<tr>
<td>Also: Modélis® Shape</td>
<td></td>
<td></td>
<td>Canada</td>
</tr>
<tr>
<td>Hyaluronic acid fillers used as comparators in split-face randomized controlled trials</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Restylane®</td>
<td>Non-cohesive (biphasic) filler, NASHA® technology; C = 20 mg/mL</td>
<td>Correction of moderate or severe wrinkles and folds, lip enhancement; to be injected into the mid-to-deep dermis</td>
<td>EU</td>
</tr>
<tr>
<td>Juvéderm® Ultra 3</td>
<td>Cohesive (monophasic) monodensified filler, Hylacross® technology; C = 24 mg/mL</td>
<td>Correction of moderate or severe wrinkles and folds, lip enhancement; to be injected into the mid-to-deep dermis</td>
<td>EU</td>
</tr>
</tbody>
</table>

Note: *The listed countries are the ones where the brand Belotero® is on the market, excluding the ones with the sister brands marketed by Anteis.

Abbreviations: CPM®, cohesive polydensified matrix; EU, European Union; HA, hyaluronic acid; NASHA®, nonanimal-stabilized hyaluronic acid; NLF, nasolabial fold.

Results

A total of 26 papers presenting original efficacy or safety clinical data on Belotero® dermal fillers were reviewed (Table 2). Performance and safety findings with Belotero® products are summarized in Table 4.

Of the 26 papers, 20 presented data on Belotero® Basic/Balance, one on Belotero® Hydro, four on Belotero® Soft, five on Belotero® Intense, and three on Belotero® Volume.

Five papers presented clinical data on more than one Belotero® dermal filler, with or without pooled results.
<table>
<thead>
<tr>
<th>Study, design, and indication</th>
<th>Treatments and population</th>
<th>Injection technique</th>
<th>Mean injected volume</th>
<th>Time points and assessments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Belotero® Basic/Balance</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RCT (and extension) with comparator(s)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prager and Steinraus9,a</td>
<td>Belotero® Basic (n=20) vs Restylane® (n=20)</td>
<td>Single injection in the mid-to-deep dermis, using the standard threading and/or multiple puncture techniques</td>
<td>1.4 mL for each product</td>
<td>Baseline, 4 weeks</td>
</tr>
<tr>
<td>RCT split-face</td>
<td>NLF</td>
<td>Mean age: 45.8 years (range 30–60 years)</td>
<td></td>
<td>NLF severity: skin topography by PRIMOS</td>
</tr>
<tr>
<td>Prager et al37,a</td>
<td>Belotero® Basic/Balance (n=20) vs Restylane® (n=20) (Arm A); Belotero® Basic/Balance (n=20) vs Juvéderm® Ultra 3 (n=20)</td>
<td>Single injection in the mid-to-deep dermis, with a 27 G needle, using the threading or multiple puncture technique</td>
<td>Arm A: 1.41 mL for Belotero®, 1.37 mL for Restylane®; Arm B: 1.42 mL for Belotero®, 1.43 mL for Juvéderm®</td>
<td>Baseline, then 6, 9, and 12 months</td>
</tr>
<tr>
<td>Arm A and Arm B: 20 patients (19 females) each</td>
<td></td>
<td></td>
<td>Arm A: 1.04 mL for Belotero®, 0.71 mL for collagen (further injections at subsequent visits)</td>
<td>NLF severity (MAS) Patient’s satisfaction, AEs</td>
</tr>
<tr>
<td>Mean age: 45.8 years (range 30–60 years) in Arm A; 45.9 years (range 35–64 years) in Arm B</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Narins et al36,b</td>
<td>Belotero® Basic/Balance vs collagen</td>
<td>Injection using cross-hatching or tunneling technique (site not specified), optional touch-up session after 2 weeks</td>
<td>1.16 mL Belotero® vs 1.37 mL collagen</td>
<td>Baseline, 2, 4, 8, 12, 16, and 24 weeks</td>
</tr>
<tr>
<td>RCT split-face</td>
<td>NLF</td>
<td>Mean age: 52.4 years (range 25.7–75.7 years)</td>
<td>Touch-up: 0.81 mL vs 0.94 mL</td>
<td>NLF severity: WSR (by blinded rater and investigator), GAIS (by blinded rater, investigator, and patient), VAS (by blinded rater, investigator, and patient) patient’s satisfaction and preference, investigator’s preference, AEs</td>
</tr>
<tr>
<td>Narins et al35,b</td>
<td>Belotero® Basic/Balance (vs collagen during RCT)</td>
<td>Touch-up injection possible at 32, 48, 72, and 96 weeks</td>
<td>At 24 weeks: 0.71 mL for Belotero®, 1.04 mL for collagen (further injections at subsequent visits)</td>
<td>NLF severity: WSR (by investigator), GAIS (by investigator and patient), treatment longevity 24 weeks (baseline), then 32, 48, 72, and 96 weeks (after primary RCT) Antibodies to HA, AEs</td>
</tr>
<tr>
<td>RCT split-face</td>
<td>Open-label extension</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NLF</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Narins et al35,b</td>
<td>Belotero® Basic/Balance vs collagen</td>
<td>Injection with 30 G needle, mostly into the superficial dermis using a serial puncture technique</td>
<td>Not reported</td>
<td>Follow-up (timing not specified) Patient’s satisfaction, AEs</td>
</tr>
<tr>
<td>Study design other than RCT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gregory39</td>
<td>Belotero® Basic/Balance</td>
<td>Injection with 30 G needle, mostly into the superficial dermis using a serial puncture technique</td>
<td>Not reported</td>
<td>Follow-up (timing not specified) Patient’s satisfaction, AEs</td>
</tr>
<tr>
<td>Observational study</td>
<td>448 patients, representing a total of 563 facial treatments Age range: 32–58 years</td>
<td>Injection with 30 G needle, mostly into the superficial dermis using a serial puncture technique</td>
<td>Not reported</td>
<td>Follow-up (timing not specified) Patient’s satisfaction, AEs</td>
</tr>
<tr>
<td>Facial treatments (mostly NLF [45%] and lip [28%])</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dirting et al33</td>
<td>Belotero® Basic</td>
<td>Injection in the mid dermis without overcorrection, using linear technique, stratum technique, or a combination of both No touch-up allowed</td>
<td>1 mL on each side</td>
<td>Baseline, post-injection, then at 2, 4, 12, and 24 weeks, follow-up at 36 weeks optional WSR (by blinded rater), GAIS (by investigators and by patients) Tolerability, AEs</td>
</tr>
<tr>
<td>Prospective study</td>
<td>114 patients (90% females) mean ± SD age: 50.2±7.1 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study, design, and indication</td>
<td>Treatments and population</td>
<td>Injection technique</td>
<td>Mean injected volume</td>
<td>Time points and assessments</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>---------------------------</td>
<td>--------------------</td>
<td>---------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>Kühne et al[^28] Retrospective study Facial treatments (mostly NLF [25%] and marionette lines [18%])</td>
<td>Belotero® Basic / Balance</td>
<td>Injection intradermally or superficially subdermally, with sharp needles (27, 28, or 30 G depending on the depth of injection and area to be treated), using microdroplet, linear threading, fanning, cross-hatching, or bolus</td>
<td>0.2–3.0 mL depending on the area treated</td>
<td>5-Year review Performance not formally assessed AEs</td>
</tr>
<tr>
<td>Downie et al[^24] Open-label study NLF</td>
<td>Belotero® Basic/Balance</td>
<td>Multiple injection in the mid-to-deep dermis with a 27 or 30 G needle, optional touch-up session after 2 weeks</td>
<td>Up to 3 mL per NFL over two sessions</td>
<td>Baseline, 2, 4, 8, 12, 16, and 24 weeks NLF severity: WSRS (by investigator and independent rater), GAIS (by patient) AEs</td>
</tr>
<tr>
<td>Gilbert and Calvisi[^42] Case series Facial treatments (mostly mid-face [71%])</td>
<td>Belotero® Balance (n=1), Restylane® + lidocaine (n=1), Perlane® + lidocaine (n=1), Juvederm® Voluma/Volift/Volbella + lidocaine (n=3), Radiesse® (n=1)</td>
<td>Belotero® Basic/Balance injected into the lips with a 32 G needle</td>
<td>1 mL</td>
<td>Discussion regarding the choice of each filler (no formal efficacy assessments)</td>
</tr>
<tr>
<td>Goh et al[^32] Retrospective chart review Infracrural hollow</td>
<td>Belotero® Balance (n=5) and Restylane®-L (n=5)</td>
<td>Injection along or 2–6 mm below the infraorbital rim, with 30 G needle using a combination of direct serial puncture and retrograde linear threading technique</td>
<td>1 mL of filler (0.5 on each side)</td>
<td>Before and immediately after injection Distribution pattern of filler by high-resolution ultrasound AEs</td>
</tr>
<tr>
<td>Hevia et al[^43] Prospective study Infracrural hollow</td>
<td>Belotero® Balance</td>
<td>Repeated injections with a 30 G needle, using retrograde injection technique Generally three to five entry sites medially, two to three centrally, three to five laterally; repeated as often as needed to correct the deficient volume</td>
<td>0.92 mL on each side at baseline, 0.27 mL at touch-up, and 0.21 mL at 6 months (re-treatment)</td>
<td>Baseline, 2, 8, 24, and 40 weeks Hollowness (Merz Aesthetics Infracrural Hollow Scale™) AEs</td>
</tr>
<tr>
<td>Wollina[^44] Retrospective study Tear trough</td>
<td>Belotero® Basic (n=21), Glytone® 3 (n=10), and Radiesse® (calcium hydroxyapatite, n=9)</td>
<td>Single injection with a 30 G needle, using linear threading technique Touch-up if necessary at 2 or 3 weeks</td>
<td>0.2–0.6 mL for HA fillers (different volume for Radiesse®)</td>
<td>Baseline, 2 or 3 weeks Fold severity (Hirmand's classification) AEs</td>
</tr>
<tr>
<td>Effect of lidocaine Moradi et al[^41] RCT Split-face Perioral lines</td>
<td>Belotero® Balance (BEL, n=10), Belotero® Balance with lidocaine (BEL + lidocaine, n=10), Belotero® Balance with lidocaine + epinephrine (BEL + lidocaine + epinephrine, n=10)</td>
<td>Injection with a 30 G needle, into the superficial dermis using serial punctures and linear threading techniques</td>
<td>1 mL per side</td>
<td>Baseline, days 1, 7, and 14 Patient-assessed pain, AEs</td>
</tr>
<tr>
<td>Prager and Micheels[^22] Prospective survey, split-face Facial treatments (mostly NLF [79%], marionette lines [62%])</td>
<td>Belotero® Basic/Balance with/without lidocaine</td>
<td>Technique depended on the site but was identical on both half-face, use of needle or cannula, either manually or with the aid of an injection system, most often in the superficial dermis (62.1%)</td>
<td>1 mL maximum on each side of the face, per zone</td>
<td>No specific time points (survey) Physician's experience (ease of use, distribution of product in the skin, satisfaction, etc) Patient's pain and satisfaction, AEs</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Study, design, and indication</th>
<th>Treatments and population</th>
<th>Injection technique</th>
<th>Mean injected volume</th>
<th>Time points and assessments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Belotero® Hydro</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study design other than RCT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Succi et al[^44]</td>
<td>Mesolis® Plus</td>
<td>Injection in the superficial dermis with 30 G needle, using the micropuncture technique</td>
<td>0.74 mL per session</td>
<td>Baseline, 2 weeks after sessions 2 and 3 Physician Clinical Global Assessment (by the three investigators and a blinded rater) Patient’s satisfaction, AEs</td>
</tr>
<tr>
<td>Open-label study</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Periorbital area</td>
<td>20 patients (all females)</td>
<td>Mean age: 50 years (range 29–59 years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Belotero® Soft (and/or other Belotero® dermal fillers)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bezzola and Micheels[^27,29]</td>
<td>Esthélis® Basic and Soft</td>
<td>Injection with 27 or 30 G needle into the superficial dermis, blanket method with the whitening technique, or into the middle or deep dermis, using point-by-point injection (Soft) or retro-tracing or prograde technique (Basic)</td>
<td>Soft: 0.1–0.6 mL per treatment session, one or two treatment sessions Basic: 0.3–1.5 mL, one or two treatment sessions</td>
<td>Baseline, day 180 (~6 months) Soft: performance not formally assessed Basic: persistence of treatment effect over time Safety based on physician’s experience (no formal count of AEs)</td>
</tr>
<tr>
<td>Open-label study</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Facial treatments</td>
<td>36 patients</td>
<td>Soft, n=11 (ten females) Basic, n=25 (20 females) Age not provided</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Micheels[^26,29,32]</td>
<td></td>
<td>Single injection with 30 G needle (for the patients who did the follow-up)</td>
<td>Not reported</td>
<td>24 months safety follow-up 74 injections (Basic 65 injections, Soft nine injections) in the 13 patients Average treatment duration: 13.3 months AEs</td>
</tr>
<tr>
<td>Safety follow-up report</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Facial treatments</td>
<td>13 patients (ten females) out of the 36 included in the pilot study</td>
<td>Mean age: 55 years (range 40–71 years)</td>
<td>Regular treatments until month 24 (5.7 injections per patients on average)</td>
<td></td>
</tr>
<tr>
<td>Hasson and Romero[^25]</td>
<td></td>
<td>Injection with 30 G needle into the superficial or mid dermis, using linear threading, serial puncture, or a combination of both Injected volume depended on the depth and extension of the scar</td>
<td>Baseline, 1 week, and 1 month Investigator’s satisfaction Patient’s satisfaction Patient-assessed pain, AEs</td>
<td></td>
</tr>
<tr>
<td>Prospective study</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Facial atrophic scars</td>
<td>12 patients</td>
<td>Age: 18–56 years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pavicic et al[^30]</td>
<td></td>
<td>Sequential approach: Bocouture® first, then Radiesse® 1 month later, and Belotero® 2–4 weeks later</td>
<td>Soft: 0.1–0.2 mL per site Basic: 0.05–0.85 mL Intense: 0.1–0.65 mL</td>
<td>Baseline, at each treatment visit, then 11 or 14 days after the last treatment Fold severity by independent rater (MAS) Tolerability (safety results not detailed)</td>
</tr>
<tr>
<td>Case series</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Whole-face rejuvenation</td>
<td>Belotero® (Soft/Basic/Intense) after Bocouture® (botulinum toxin) and Radiesse® (calcium hydroxyapatite)/[Bocouture® + Radiesse®] + Belotero® Soft, Basic, and Intense (Patient A), Belotero® Basic and Intense (Patient B), or Belotero® Soft and Basic (Patient C)</td>
<td>Sequential approach: Bocouture® first, then Radiesse® 1 month later, and Belotero® 2–4 weeks later</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Three patients (all females)</td>
<td>Age: 59, 46, and 52 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Belotero® Intense</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RCT with comparator(s)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Buntrock et al[^19]</td>
<td>Belotero® Intense vs Perlane®</td>
<td>Single injection in deep dermis, using 27 G needle and standard serial puncture technique</td>
<td>1 mL per side</td>
<td>Baseline, 2, 24, and 48 weeks NLF severity: WSRs (blinded investigator, blinded rater, and patient), skin topography (PRIMOS) Patient’s satisfaction, pain after injection, AEs</td>
</tr>
<tr>
<td>RCT split-face NLF</td>
<td>20 patients (18 females)</td>
<td>Mean age: 52.0±5.6 years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study design other than RCT</td>
<td>Treatments and population</td>
<td>Injection technique</td>
<td>Mean injected volume</td>
<td>Time points and assessments</td>
</tr>
<tr>
<td>----------------------------</td>
<td>---------------------------</td>
<td>--------------------</td>
<td>---------------------</td>
<td>----------------------------</td>
</tr>
<tr>
<td>Pavicic et al(^a)</td>
<td>Belotero(^®) Basic and Belotero(^®) Intense combined</td>
<td>Case 1: three syringes Basic at baseline, then two and one syringes Basic at 6 and 12 months, respectively, then two syringes Intense at 18 months; no further treatment at 30 months</td>
<td>Up to 2 mL at each treatment session, in both cases</td>
<td>Case 1: baseline, then 6, 12, 18, and 30 months</td>
</tr>
<tr>
<td>Case series</td>
<td>Two HIV-infected patients</td>
<td></td>
<td></td>
<td>Case 2: baseline, then 8, 20, and 26 months</td>
</tr>
<tr>
<td>HIV-associated facial lipoatrophy</td>
<td>Case 1: 38-year-old man</td>
<td>Injection in the mid-to-deep dermis, with a Kendall-type 27 G needle, using preferably the retrograde tunneling (or slow local infiltration to create volume)</td>
<td>Reported for some patients but not the whole sample</td>
<td>Severity of the facial lipoatrophy (facial lipoatrophy severity scale) AEs</td>
</tr>
<tr>
<td>Case 2: 56-year-old man</td>
<td>Injection technique Mean injected volume</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Micheels(^a)</td>
<td>Fortélis(^®) Extra</td>
<td>Injection of Belotero(^®) Intense into the deep dermis with a 27 G needle, using various techniques: linear threading, serial puncture, fanning, criss-cross, or the sandwich technique (Intense first, then Basic into the mid dermis)</td>
<td>1 mL on each side (range 0.3–5.0 mL)</td>
<td>Baseline, immediately after injection, and at 2 and 12 weeks</td>
</tr>
<tr>
<td>Observational study (+ histology)</td>
<td>28 patients (20 females)</td>
<td>With sandwich technique: 0.73 mL of Basic (range 0.3–1.0 mL)</td>
<td>Efficacy: baseline, 6 months, ≥10 months Esthetic improvement discussed but not quantified Histology: day 0, day 90 AEs</td>
<td>Fold severity: WSRs, GAIS Overall esthetic effect (by physician) Investigator’s satisfaction Patient’s satisfaction, AEs</td>
</tr>
<tr>
<td>Facial treatments</td>
<td>Mean age: 53 years (range 33–67 years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>One patient for histology (skin of the thigh)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pavicic(^b)</td>
<td>Belotero(^®) Intense alone (n=110) or combined with Belotero(^®) Basic (sandwich procedure, n=39)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Open-label study</td>
<td>Injection technique Mean injected volume</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Facial treatments (mostly NLF [84%])</td>
<td>149 patients (88.9% females)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean age: 52.2 years (range 25–77 years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Belotero(^®) Volume</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study design other than RCTs</td>
<td>Belotero(^®) Volume</td>
<td>Majority of injections performed at a deep dermal/hypodermal depth or to the level of the supraperiosteal plane, using needle or cannula (most common size: 27 G, 46.3% of cases; 25 G, 25.9% of cases)</td>
<td>0.58 mL per side</td>
<td>Baseline, 1, 3, and 6 months Esthetic effect: FVLS by investigator, GAIS by investigator and patient Patient’s satisfaction Investigator’s experience AEs</td>
</tr>
<tr>
<td>Micheels(^a)</td>
<td>56 patients</td>
<td>Optional touch-up at 1 month (n=2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Observational study</td>
<td>Facial volume loss (mostly cheeks [38.6%], cheekbones [18.1%], tear trough [18.1%])</td>
<td>Mean age: 59.8±13.6 years (range: 25–76 years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Modélis(^®) Shape</td>
<td>Ten male patients</td>
<td>Subdermal injection in submalar area with 25 G short needle completed with 22 G microcannula of 50 mm length, using a retrograde and fanning technique, optional touch-up session after 2 weeks Two or three punctures per session</td>
<td>1.3 mL per cheek</td>
<td>Baseline, 1, 6, and 12 months HA volume, skin thickness, and tissue vascularization by MRI Patient’s satisfaction GAIS (by investigator and patient) AEs</td>
</tr>
<tr>
<td>Becker et al(^a)</td>
<td>Mean age: 56.4±6.4 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Observational study</td>
<td>HIV-associated facial lipoatrophy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Modélis(^®) Shape</td>
<td>Ten male patients</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean age: 56.4±6.4 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Micheels et al(^a)</td>
<td>20 patients</td>
<td>Injection in lateral cheek hollow (n=8), cheekbone area (n=6), or both (n=6), with needles and cannulae, using different methods depending on the investigator. Optional touch-up injection</td>
<td>2.1 mL for both sides for injection in lateral cheek hollow, 2.1 mL for injection in cheekbone area, 3.37 mL for injection in both</td>
<td>Baseline, immediately after injection, and 1, 3, 6, 9, 12 (and optionally 18) months Esthetic effect: FVLS by investigator, GAIS by investigator and patient Patient’s satisfaction AEs</td>
</tr>
<tr>
<td>Post-marketing clinical follow-up</td>
<td>20 patients</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean age: 57 years (range 28–73 years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Note:** \(^{a}\) Studies with the same superscript letter were conducted in the same patients (eg, RCT and extension study).

**Abbreviations:** AEs, adverse events; FVLS, Facial Volume Loss Scale; GAIS, Global Aesthetic Improvement Scale; HA, hyaluronic acid; MAS, Merz Aesthetics Scales; MRI, magnetic resonance imaging; NLF, nasolabial fold; PRIMOS, phase-shift rapid in vivo measurement of skin; RCT, randomized controlled trial; VAS, visual analog scale; WSRs, Wrinkle Severity Rating Scale.
(Esthélis® Basic and Soft,25–27 Belotero® Basic/Balance, and Intense28,29), and one paper presented data on a combination of products (Belotero® dermal filler injected after botulinum toxin and calcium hydroxyapatite30).

In all but two studies,31,32 the Belotero® dermal fillers did not contain lidocaine, since the addition of lidocaine to the Belotero® range is relatively recent (April 2014 for Belotero® Basic/Balance and Belotero® Intense, January 2015 for Belotero® Volume).

### Table 3 Performance assessment of dermal fillers: rating scales, and investigator’s and patient’s satisfaction

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Description</th>
<th>End points/definition</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rating scales</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WSRS</td>
<td>Discrete 5-point scale</td>
<td>Fold severity From 0 – absent (no visible fold; continuous skin line), to 4 – extreme (extremely deep and long folds detrimental to facial appearance to 4 mm V-shaped fold when stretched)</td>
<td>58</td>
</tr>
<tr>
<td>GAIS (not validated)</td>
<td>Discrete 5-point scale</td>
<td>Esthetic outcomes compared to baseline From 1 – worse to 5 – very much improved</td>
<td></td>
</tr>
<tr>
<td>VAS fill state</td>
<td>Continuous scale (0%–100%)</td>
<td>Fold correction (ie, improvement) rated from 0% to 100%</td>
<td></td>
</tr>
<tr>
<td>Overall esthetic effect</td>
<td>Discrete 6-point scale</td>
<td>From 1 – excellent to 6 – unsatisfactory</td>
<td></td>
</tr>
<tr>
<td>FVLS</td>
<td>Discrete 5-point scale</td>
<td>From 1 – mild flattening/no visibility of underlying tissue, to 5 – severe indentation of one or more facial regions/clear visibility of underlying tissue</td>
<td>59</td>
</tr>
<tr>
<td>Facial lipoatrophy severity scale</td>
<td>Discrete 4-point scale</td>
<td>From 1 – mild and localized facial lipoatrophy, to 4 – lipoatrophy covers a wide area, extending up toward the eye sockets, and the facial skin lies directly on the muscles</td>
<td></td>
</tr>
<tr>
<td>MAS</td>
<td>Discrete 5-point scale</td>
<td>Scales for the lower face (NLFs, marionette lines, upper and lower lip fullness, lip wrinkles, oral commissures, and jawline) Scales for the mid face (infraorbital hollow and upper and lower cheek fullness) Scales for the upper face (forehead lines, glabellar lines, crow’s feet, sex-specific brow positioning, and summary scores of forehead and crow’s feet areas and of the entire upper face unit)</td>
<td>60–62</td>
</tr>
<tr>
<td>Hirmand’s classification</td>
<td>Discrete 3-point scale</td>
<td>Severity of tear trough deformity From Class I – loss of volume limited medially down to Class III – full depression circumferentially to the orbital rim</td>
<td>63</td>
</tr>
<tr>
<td>Physician’s clinical global assessment</td>
<td>Discrete 7-point scale</td>
<td>Rating of skin’s appearance (brightness, texture, and turgor), from 100% improvement down to worsening</td>
<td></td>
</tr>
<tr>
<td><strong>Satisfaction with the product (and related factors)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Practitioner’s satisfaction</td>
<td>Ease of use, esthetic outcomes, etc</td>
<td>Overall satisfaction/preference</td>
<td></td>
</tr>
<tr>
<td>Patient’s satisfaction</td>
<td>Various assessments</td>
<td>Overall satisfaction/preference Specific questions such as whether the patient felt the implant, whether the patient would recommend the treatment, whether the patient’s expectations were met and he/she would repeat the treatment course Quality-of-life questionnaire</td>
<td></td>
</tr>
<tr>
<td>Pain (VAS)</td>
<td>Discrete 11-point scale</td>
<td>0 – no pain to 10 – worst imaginable pain</td>
<td></td>
</tr>
<tr>
<td>Treatment longevity</td>
<td>Various assessments</td>
<td>Percentage of patients not requiring injections; percentage of patients who persist without repeat treatment for a given length of time; cumulative number of injections received for a given length of time; average time between injections; time lag between the first and the second treatment sessions</td>
<td></td>
</tr>
</tbody>
</table>

Note: The last column (“Reference”) refers to the publication describing/validating the scale, if any.

Abbreviations: FVLS, Facial Volume Loss Scale; GAIS, Global Aesthetic Improvement Scale; MAS, Merz Aesthetics Scales; NLF, nasolabial fold; VAS, visual analog scale; WSRS, Wrinkle Severity Rating Scale.

Belotero® Basic/Balance

Among the 20 studies that investigated the performance and safety of Belotero® Basic/Balance, six were focused on nasolabial folds (NLFs),26,33–37 five on various facial areas,26,27,32,38,39 two on infraorbital hollow,23,40 one on tear trough,41 one on lip volume restoration,42 one on perioral lines,31 and one on atrophic scars.25 In addition, three studies presented data on Belotero® Basic/Balance combined to other Belotero® dermal fillers for deep lines and wrinkles.
Safety and efficacy of Belotero® fillers: a review

Filling,28 whole-face rejuvenation,29 or HIV-associated facial lipoatrophy.29

The state of the literature is consistent with the indications most frequently treated with Belotero® Basic/Balance. In a 5-year chart review including 317 patients and 668 treatments, the areas most commonly treated were the NLFs (166 treatments, 24.9%), the marionette lines (122 treatments, 18.3%), and the perioral lines (106 treatments, 15.9%).38

Performance of Belotero® Basic/Balance

Nasolabial folds

Two randomized controlled trials (RCTs) using a split-face design have been conducted on Belotero® Basic/Balance, with other HA fillers (Restylane®, Juvéderm® Ultra 3, n=20 per arm)9,37 and bovine collagen (n=118)35,36 as comparators. In both cases, the treated area was the NLF, which was rated as moderate to severe at baseline.

Short-term performance of the fillers was evaluated immediately after injection and after 2–4 weeks. To assess treatment longevity, further assessments were regularly performed, with a last evaluation at 6,36 12,37 and up to 22 months (ie, 96 weeks).35

Based on skin topography, the mean reduction in the wrinkle depth at 4 weeks was shown to be greater with Belotero® Basic/Balance (−109.5 µm) than with Restylane® (−71.8 µm, P<0.0001; Figure 1 and Table 4).9

Positive findings were also reported using quantitative scales (Figure 2). Greater changes in WSRS scores (assessed by a blinded rater) were obtained with Belotero® Basic/Balance than with collagen, 8, 12, 16, and 24 weeks after injection (P<0.01).36 These results were globally confirmed by the Global Aesthetic Improvement Scale (GAIS) scores and the visual analog scale fill state scores (Table 4).36 Lower scores on Merz Aesthetics Scales were obtained at 4 weeks than at baseline with Belotero® Basic/Balance, Restylane®, and Juvéderm® Ultra 3, with no statistically significant differences between fillers.37

Regarding treatment longevity, the fold severity scores were still lower than at baseline for Belotero® Basic/Balance, Restylane®, and Juvéderm® Ultra 3 up to 12 months after injection (1.5 or 1.6 vs 2.3 at baseline, respectively).37 In the open-label 18-month extension study, with re-treatment at 24 weeks and optional touch-up injections thereafter, treatment effects persisted without re-treatment for at least 48 weeks in 80.2% of patients, both with Belotero®
### Table 4 Belotero® dermal fillers: summary of clinical findings

<table>
<thead>
<tr>
<th>Study, design, and indication</th>
<th>Treatments and performance</th>
<th>Pain, safety, and tolerability</th>
<th>Investigator’s and patient’s satisfaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Belotero® Basic/Balance</td>
<td>Belotero® Basic (n=20) vs Restylane® (n=20)</td>
<td>Pain immediately after injection (by VAS): lower with Belotero® (ns)</td>
<td>Patient’s satisfaction: felt the implant: 65% with Belotero®, 75% with Restylane® 55% would recommend both products Of those who would recommend one product: 25% Belotero®, 10% Restylane®</td>
</tr>
<tr>
<td>Prager and Steinkrusssa</td>
<td>Belotero® Basic (n=20) vs Restylane® (n=20)</td>
<td>Most common AEs: injection-site erythema (Belotero® n=7.35%; Restylane® n=6.30%), hematoma (Belotero® n=1.5%; Restylane® n=2.10%)</td>
<td>No SAes, no AEs leading to discontinuation</td>
</tr>
<tr>
<td>RCT split-face NLF</td>
<td>Belotero® Basic (n=20) vs Restylane® (n=20)</td>
<td>All AEs of mild or moderate severity No SAes, no AEs leading to discontinuation Tolerability rated as good/very good by 85% of patients with Belotero® vs 80% of patients with Restylane® (and in 90% of cases with both treatments, by the investigators)</td>
<td></td>
</tr>
<tr>
<td>Narins et al36b</td>
<td>Belotero® Basic/Balance vs collagen (n=118)</td>
<td>Most AEs of mild or moderate severity, except one severe AE (pain in one patient with Belotero® in Arm B). No SAes, no AEs leading to discontinuation</td>
<td>Patient’s questionnaire (n=107): 79.4% preferred Belotero® at 24 weeks. Improvement and satisfaction (VAS) rated at 74.7% and 78.2% with Belotero® vs 66.0% and 65.1% with collagen Five out of six investigators preferred Belotero® because of its storage and handling, and comfort, and design of its syringe (two out of six investigators also preferred Belotero® because of the ease of injection)</td>
</tr>
<tr>
<td>RCT split-face NLF</td>
<td>Belotero® Basic/Balance vs collagen (n=118)</td>
<td>Injection-site pain: 44.9% with Belotero®, 53.4% with collagen; generally mild to moderate Related AEs in ≥2% of full analysis set: 167 AEs with Belotero®, 217 AEs with collagen Injection-site AEs (Belotero® vs collagen): nodule (33.1% vs 55.1%), induration (33.9% vs 40.7%), swelling (22.9% vs 22.0%), pruritus (5.1% vs 7.6%), pain (5.1% vs 4.2%), erythema (2.5% vs 4.2%), bruising (3.4% vs 0.8%), discoloration (0% vs 4.2%)</td>
<td>No preference: Arm A 10%, Arm B 0%</td>
</tr>
<tr>
<td>Prager et al37a</td>
<td>Belotero® Basic/Balance (n=20) vs Restylane® (n=20) (Arm A); Belotero® Basic/Balance (n=20) vs Juvéderm® Ultra 3 (n=20)</td>
<td>Patient’s satisfaction: both fillers acceptable: Arm A 55%, Arm B 25% Preferred Belotero®: Arm A 25%, Arm B 40% Preferred other filler: Arm A Restylane® 10%, Arm B Juvéderm® 35%</td>
<td>Patient’s satisfaction: felt the implant: 65% with Belotero®, 75% with Restylane® 55% would recommend both products Of those who would recommend one product: 25% Belotero®, 10% Restylane®</td>
</tr>
<tr>
<td>RCT, split-face NLF</td>
<td>Belotero® Basic/Balance (n=20) vs Restylane® (n=20) (Arm B)</td>
<td>NLF severity: lowest score obtained at week 4, regardless of the filler (0.8 or 0.9, depending on Arm). Scores still lower at 12 months (1.5 or 1.6) than at baseline (2.3), for all fillers No statistical difference between fillers</td>
<td></td>
</tr>
<tr>
<td>NLF</td>
<td>Belotero® Basic/Balance vs collagen (n=118)</td>
<td>Change in WRST at 12 weeks (by blinded rater) greater with Belotero® (P&lt;0.001): from 2.50 to 1.25 (~1.25) vs 2.49 to 1.51 (~0.98) with collagen Other significant differences in favor of Belotero®: WRST (blinded rater) at 8, 12, 16, and 24 weeks; WSRS (investigator) at 12, 16, and 24 weeks; GAIS (blinded rater and investigator) at 8, 12, 16, and 24 weeks; GAIS (patient) at 8, 16, and 24 weeks; VAS fill state (blinded rater, investigator, and patient) at 8, 12, 16, and 24 weeks (except patient VAS at week 8) Responder rate (% of patients showing a difference in WRST of ≥1 point between Belotero® and collagen): 15.9% at 2 weeks, 55.1% at 24 weeks</td>
<td></td>
</tr>
<tr>
<td>Narins et al36b</td>
<td>Belotero® Basic/Balance vs collagen (n=118)</td>
<td>Change in WSRS at 12 weeks (by blinded rater) greater with Belotero® (P&lt;0.001): from 2.50 to 1.25 (~1.25) vs 2.49 to 1.51 (~0.98) with collagen Other significant differences in favor of Belotero®: WRST (blinded rater) at 8, 12, 16, and 24 weeks; WSRS (investigator) at 12, 16, and 24 weeks; GAIS (blinded rater and investigator) at 8, 12, 16, and 24 weeks; GAIS (patient) at 8, 16, and 24 weeks; VAS fill state (blinded rater, investigator, and patient) at 8, 12, 16, and 24 weeks (except patient VAS at week 8) Responder rate (% of patients showing a difference in WRST of ≥1 point between Belotero® and collagen): 15.9% at 2 weeks, 55.1% at 24 weeks</td>
<td></td>
</tr>
<tr>
<td>NLF</td>
<td>Belotero® Basic/Balance vs collagen (n=118)</td>
<td>Change in WRST at 12 weeks (by blinded rater) greater with Belotero® (P&lt;0.001): from 2.50 to 1.25 (~1.25) vs 2.49 to 1.51 (~0.98) with collagen Other significant differences in favor of Belotero®: WRST (blinded rater) at 8, 12, 16, and 24 weeks; WSRS (investigator) at 12, 16, and 24 weeks; GAIS (blinded rater and investigator) at 8, 12, 16, and 24 weeks; GAIS (patient) at 8, 16, and 24 weeks; VAS fill state (blinded rater, investigator, and patient) at 8, 12, 16, and 24 weeks (except patient VAS at week 8) Responder rate (% of patients showing a difference in WRST of ≥1 point between Belotero® and collagen): 15.9% at 2 weeks, 55.1% at 24 weeks</td>
<td></td>
</tr>
<tr>
<td>Study, design, and indication</td>
<td>Treatments and performance</td>
<td>Pain, safety, and tolerability</td>
<td>Investigator’s and patient’s satisfaction</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>---------------------------</td>
<td>-------------------------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td>Narins et al&lt;sup&gt;33b&lt;/sup&gt;</td>
<td>Belotero&lt;sup&gt;®&lt;/sup&gt; Basic/Balance (vs collagen during RCT)</td>
<td>RCT (n=95 out of the 106 completers of RCT)</td>
<td>Not assessed</td>
</tr>
<tr>
<td>Open-label extension RCT</td>
<td>At weeks 32, 48, 72, and 96, decrease in NLF severity on both sides, but greater with Belotero&lt;sup&gt;®&lt;/sup&gt; (statistical comparison not performed)</td>
<td>34 AEs reported in 24.2% of patients</td>
<td></td>
</tr>
<tr>
<td>NLF</td>
<td>Mean GAIS score (by investigator) was at 2 (improved) or 3 (much improved) at all time points. Better results on Belotero&lt;sup&gt;®&lt;/sup&gt; side (according to either GAIS investigator or GAIS patient)</td>
<td>Only one AE (2.9%) considered related: injection-site bruising, on both sides of the face (moderate severity, resolved within 3 days)</td>
<td>Not assessed</td>
</tr>
<tr>
<td></td>
<td>Predictors of longevity: 80.2% of patients persisted without treatment for an interval of 48 weeks, regardless of treatment</td>
<td>Antibodies to HA at week 32 (n=79): no detectable anti-HA IgG antibodies in 86.1% of patients; borderline positive in 10.1% (pretreatment)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>In the 10.1%, three patients had positive anti-HA titers, with only one patient showing significant increase pre- to posttreatment</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anti-HA IgE antibodies: assays all negative</td>
<td></td>
</tr>
<tr>
<td>Study design other than RCT</td>
<td>Belotero&lt;sup&gt;®&lt;/sup&gt; Basic/Balance (n=448)</td>
<td>Exact count of AEs not provided</td>
<td>Of the 475 patients, 473 were satisfied or more than satisfied. (note: results in contradiction with the sample size reported in the methods, n=448)</td>
</tr>
<tr>
<td>Gregory&lt;sup&gt;39&lt;/sup&gt;</td>
<td>Performance not formally assessed</td>
<td>Short-term AEs (within 1 month): swelling, redness, and bruising (only three AEs lasted for ≥24 hours)</td>
<td></td>
</tr>
<tr>
<td>Observational study</td>
<td>No patient returned between months 1 and 3 because of early reabsorption of the product</td>
<td>No infection, lumps, or product migration</td>
<td></td>
</tr>
<tr>
<td>Facial treatments (mostly NLF [45%] and lip [28%])</td>
<td>Belotero&lt;sup&gt;®&lt;/sup&gt; Basic/Balance (n=14, with 109 completed treatment period, 35 completers of 36-week follow-up)</td>
<td>Long-term AEs (ie, persisted for ≥1 month after injection): no infection, granuloma, persistent lumps</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Related AEs in 61% of patients</td>
<td>Not assessed</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Most common AEs: hematoma, erythema, swelling, and induration of mild intensity</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>No AEs leading to discontinuation</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>No related SAEs during the study, nor the follow-up</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>After 2 weeks, AEs reported in 23% of patients. After 6 months, only two AEs reported (one discoloration, one nodule)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tolerability considered good/very good by the investigators in 96% of patients at 24 weeks</td>
<td></td>
</tr>
<tr>
<td>Ding et al&lt;sup&gt;13&lt;/sup&gt;</td>
<td>Belotero&lt;sup&gt;®&lt;/sup&gt; Basic (11 of 14 patients)</td>
<td>Most common AEs: erythema, edema, ecchymosis</td>
<td>Not formally assessed</td>
</tr>
<tr>
<td>Prospective study</td>
<td>% of patients with improvement in WRS at of ≥1 point: 100% after injection, 97% at 2 and 4 weeks, 91% at 12 weeks, and 81% at 24 weeks</td>
<td>(all of short duration, count not provided)</td>
<td></td>
</tr>
<tr>
<td>NLF</td>
<td>Percentage down to 66% in the 35 patients who did the follow-up (other patients were back to their baseline score)</td>
<td>No persisting nodules, no granulomas, no Tyndall effect</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tolerability considered good/very good by the investigators in 96% of patients at 24 weeks</td>
<td></td>
</tr>
<tr>
<td>Kühne et al&lt;sup&gt;13&lt;/sup&gt;</td>
<td>Belotero&lt;sup&gt;®&lt;/sup&gt; Basic/Balance (n=317)</td>
<td>No SAEs</td>
<td></td>
</tr>
<tr>
<td>Retrospective study</td>
<td>Performance not formally assessed</td>
<td>No AEs leading to discontinuation</td>
<td></td>
</tr>
<tr>
<td>Facial treatments</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Most common AEs: erythema, edema, ecchymosis (all of short duration, count not provided)</td>
<td></td>
</tr>
<tr>
<td>Downie et al&lt;sup&gt;34&lt;/sup&gt;</td>
<td>Belotero&lt;sup&gt;®&lt;/sup&gt; Basic/Balance (n=93)</td>
<td>Related AEs in 77.4% of patients; most frequent (&gt;50% of patients): swelling, induration, and pain at injection site</td>
<td>Not assessed</td>
</tr>
<tr>
<td>Open-label study</td>
<td>WRS: improvement at 2, 4, 8, 12, 16, and 24 weeks for both NLFs, according to investigator and independent rater.</td>
<td>AEs related to injection in 32.3% of patients; most frequent (&gt;10% of patients): bruising and discoloration. Systemic AEs in 11.8% of patients, all unrelated. No SAEs</td>
<td></td>
</tr>
<tr>
<td>NLF</td>
<td>GAIS: same results as WRS, based on the patient’s assessment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gilbert and Calvisi&lt;sup&gt;42&lt;/sup&gt;</td>
<td>Belotero&lt;sup&gt;®&lt;/sup&gt; Balance (n=1), Restylane&lt;sup&gt;®&lt;/sup&gt; + lidocaine (n=1), Perlane&lt;sup&gt;®&lt;/sup&gt; + lidocaine (n=1), Juvederm&lt;sup&gt;®&lt;/sup&gt; Voluma/Volift/Volbella</td>
<td>AE reported in four out of seven cases: minimal trauma (Juvederm&lt;sup&gt;®&lt;/sup&gt; Voluma + lidocaine n=1); minimal post-injection bleeding (Juvederm&lt;sup&gt;®&lt;/sup&gt; Volift + lidocaine n=1); moderate swelling (Restylane&lt;sup&gt;®&lt;/sup&gt; + lidocaine n=1); moderate bruising with no vascular compromise (Radiesse&lt;sup&gt;®&lt;/sup&gt;, n=1)</td>
<td>Not assessed</td>
</tr>
<tr>
<td>Case series</td>
<td></td>
<td>No AE reported with Belotero&lt;sup&gt;®&lt;/sup&gt; Balance and Juvederm&lt;sup&gt;®&lt;/sup&gt; Volbella + lidocaine</td>
<td></td>
</tr>
<tr>
<td>Facial treatments (mostly mid face [71%])</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Study, design, and indication</th>
<th>Treatments and performance</th>
<th>Pain, safety, and tolerability</th>
<th>Investigator’s and patient’s satisfaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Goh et al&lt;sup&gt;22&lt;/sup&gt; Retrospective chart review</td>
<td>Belotero&lt;sup&gt;®&lt;/sup&gt; Balance (n=5) and Restylane&lt;sup&gt;®&lt;/sup&gt;-L (n=5)</td>
<td>Only reported AE: edema, ~2 weeks after injection (Belotero&lt;sup&gt;®&lt;/sup&gt; n=1; Restylane&lt;sup&gt;®&lt;/sup&gt; n=1)</td>
<td>Not assessed</td>
</tr>
<tr>
<td>Infraorbital hollow</td>
<td>Belotero&lt;sup&gt;®&lt;/sup&gt; Basic/Balance spread more widely in the tissue plane, compared to Restylane&lt;sup&gt;®&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Belotero&lt;sup&gt;®&lt;/sup&gt;: “elongated, spindle-shaped configuration”</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Restylane&lt;sup&gt;®&lt;/sup&gt;: “bubble or pearl-like configuration”</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Belotero&lt;sup&gt;®&lt;/sup&gt; Balance (n=49, with 46 completers)</td>
<td>Mild-to-moderate delayed swelling (n=4) at 2 weeks, which resolved within 2–10 months</td>
<td>Two-thirds of patients did not elect complimentary additional treatment at 6 months (but remained in the study for analysis)</td>
</tr>
<tr>
<td>Hevia et al&lt;sup&gt;40&lt;/sup&gt; Prospective study</td>
<td>Decrease in hollowness from baseline (P&lt;0.001)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infraorbital hollow</td>
<td>At 2 months, an improvement in hollowness of ≥1 point was seen in 76.1% of patients (and ≥2 points in 19.6%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>At 10 months, 27 out of 31 (87%) patients still showed an improvement of ≥1 point</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wollina 41 Retrospective study</td>
<td>Belotero&lt;sup&gt;®&lt;/sup&gt; Basic (n=21), Glytone&lt;sup&gt;®&lt;/sup&gt; 3 (n=10), and Radiesse&lt;sup&gt;®&lt;/sup&gt; (calcium hydroxyapatite, n=9)</td>
<td>AEs in 25 out of 31 patients (80.6%) with HA fillers (Belotero&lt;sup&gt;®&lt;/sup&gt; and Glytone&lt;sup&gt;®&lt;/sup&gt; pooled): bruising (n=13), edema (n=6), and redness (n=6)</td>
<td>38 out of 40 patients (95%) were very satisfied with HA fillers (data not provided for Belotero&lt;sup&gt;®&lt;/sup&gt; alone)</td>
</tr>
<tr>
<td>Tear trough</td>
<td>Average improvement: 1 class on the Herrmand’s classification; 12 patients originally in Class II had a 2-class improvement</td>
<td>All AEs mild and temporary; resolved within 2–3 weeks without treatment</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Duration of effect: between 9 and 12 months with HA fillers (10.1±2.4 months), and between 11 and 15 months with Radiesse&lt;sup&gt;®&lt;/sup&gt; (12.8±3.9 months)</td>
<td>No Tyndall effect, bumps, or nodules</td>
<td></td>
</tr>
<tr>
<td>Effect of lidocaine</td>
<td>Belotero&lt;sup&gt;®&lt;/sup&gt; Balance (BEL, n=10), Belotero&lt;sup&gt;®&lt;/sup&gt; Balance with lidocaine (BEL + lido, n=10), Belotero&lt;sup&gt;®&lt;/sup&gt; Balance with lidocaine + epi (BEL + lido + epi, n=10)</td>
<td>No significant difference in pain and bruising scores between treatments</td>
<td>Not assessed</td>
</tr>
<tr>
<td>Moradi et al&lt;sup&gt;31&lt;/sup&gt; RCT split-face</td>
<td>Not assessed</td>
<td>No lumps or nodules reported</td>
<td></td>
</tr>
<tr>
<td>Perioral lines</td>
<td>Belotero&lt;sup&gt;®&lt;/sup&gt; Basic/Balance with or without lidocaine (n=29), blanching technique used in 21 patients (72%)</td>
<td>Most common AEs: bruising and pain</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Physicin’s experience: Belotero&lt;sup&gt;®&lt;/sup&gt; with/without lidocaine similar in terms of injection force, texture, and placement</td>
<td>No significant difference in pain and bruising scores between treatments</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Blanching technique with lidocaine: easier than without lidocaine (n=2, similar/identical n=19)</td>
<td>No lumps or nodules reported</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Same skin distribution of products: 76% applications. Esthetic outcomes rated by investigator: similar or identical between products in all patients</td>
<td>Pain reported in 20 out of 29 patients, with lower mean pain intensity with lidocaine than without lidocaine (2.8±1.1 vs 5.8±2.1, P=0.0001)</td>
<td>Patient-assessed satisfaction (n=21): 21 patients (100%) were satisfied</td>
</tr>
<tr>
<td>Belotero&lt;sup&gt;®&lt;/sup&gt; Hydro</td>
<td>Physician’s experience: Belotero&lt;sup&gt;®&lt;/sup&gt; with/without lidocaine similar in terms of injection force, texture, and placement</td>
<td>Redness after injection in 52% of patients with both products</td>
<td></td>
</tr>
<tr>
<td>Prager and Michaels&lt;sup&gt;25&lt;/sup&gt; Prospective survey, split-face</td>
<td>Blachning technique with lidocaine: easier than without lidocaine (n=2, similar/identical n=19)</td>
<td>Bruising after injection in 10% of patients without lidocaine, and 14% of patients with lidocaine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Same skin distribution of products: 76% applications. Esthetic outcomes rated by investigator: similar or identical between products in all patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Facial treatments (mostly NLF [79%] and marionette lines [62%])</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Succi et al&lt;sup&gt;46&lt;/sup&gt; Open-label study</td>
<td>Mesoliss&lt;sup&gt;®&lt;/sup&gt; Plus (n=20, with 18 completers)</td>
<td>Mild pain during injection in ~80% of patients; one case of severe pain (during the first session). Injection-site AEs: edema (80% of all sessions, lasting for 6 days on average), hematoma (in 76% of patients, lasting for 7 days), erythema (in 10%, 0%, and 30% of patients after sessions 1, 2, and 3, respectively) Papules in most patients (lasting for 5 days). No SAes</td>
<td>Patient’s satisfaction (from 0 – worst to 10 – best): mean score of 5.9 (range: 0 in 1 patient to 8 in 4 patients)</td>
</tr>
<tr>
<td>Study, design, and indication</td>
<td>Treatments and performance</td>
<td>Pain, safety, and tolerability</td>
<td>Investigator's and patient's satisfaction</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-----------------------------</td>
<td>-----------------------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td><strong>Belotero® Soft (and/or other Belotero® dermal fillers)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bezzola and Micheleš 2014</td>
<td>Belotero Basic (n=25) and Soft (n=11)</td>
<td>No formal count of AEs</td>
<td>Not assessed</td>
</tr>
<tr>
<td>Open-label study</td>
<td>Soft: performance not formally assessed</td>
<td>Based on the physician’s experience, AEs to be expected are: minor edema, bruising/ hematoma, post-injection erythema lasting for ≤48–72 hours</td>
<td></td>
</tr>
<tr>
<td>Facial treatments</td>
<td>Basic: persistence of treatment effect over time, ranging from 3 to 7 months in the 25 patients</td>
<td>No infection, granuloma, or allergy reported</td>
<td></td>
</tr>
<tr>
<td>Micheles 2014</td>
<td>Belotero® Basic and Soft (n=13, out of the 36 included in the pilot study)</td>
<td>AEs: rare bruises, erythema (≤24 hours), very light swelling (≤24 hours) (exact count of AEs not provided)</td>
<td>Not assessed</td>
</tr>
<tr>
<td>Safety follow-up</td>
<td>Not assessed</td>
<td>No allergic reaction or granuloma</td>
<td></td>
</tr>
<tr>
<td>Facial treatments</td>
<td>Esthélis® Basic or Soft (n=12)</td>
<td>Mild or moderate pain during injection</td>
<td>Not assessed</td>
</tr>
<tr>
<td>Hasson and Romero 2012</td>
<td>Esthetic improvement rated by the investigator as moderate (27%), good (57%), or excellent (17%) immediately, 1 week, and 1 month after injection.</td>
<td>Mild erythema immediately after injection (count not reported); resolved spontaneously within a few hours. No Tyndall effect</td>
<td></td>
</tr>
<tr>
<td>Prospective study</td>
<td>Patient’s rating: moderate (17%), good (33%), or excellent (50%) immediately after injection, and good (42%) or excellent (58%) 1 week and 1 month after injection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Facial atrophic scars</td>
<td>At 11–14 days after last treatment, improvement of ≥1 point: nine out of eleven sites (82%) in Patients A and C, ten out of eleven sites (91%) in Patient B</td>
<td>Procedure well tolerated (detailed safety results not provided)</td>
<td>Not formally assessed</td>
</tr>
<tr>
<td>Pavicic et al 2013</td>
<td>Belotero® (Soft/Basic/Intense) after Bocouture® (botulinum toxin) and Radiesse® (calcium hydroxyapatite)/</td>
<td>Pain after injection lower with Belotero® than Perlane® (3.9 vs 5.0, P=0.01)</td>
<td>% of patients satisfied higher with Belotero® than Perlane® at week 24 (62% vs 51%, P=0.002) and week 48 (43% vs 33%, P=0.005) 80% of patients would repeat treatment with Belotero® vs 65% of patients with Perlane®</td>
</tr>
<tr>
<td>Case series</td>
<td>No SAes, no Aes leading to discontinuation</td>
<td>Procedure well tolerated (detailed safety results not provided)</td>
<td>Not formally assessed</td>
</tr>
<tr>
<td>Whole-face rejuvenation</td>
<td>Belotero® (Basic and Intense) after Bocouture® and Radiesse® (calcium hydroxyapatite)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Belotero® Intense</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RCT with comparator(s)</td>
<td>Belotero® Intense vs Perlane® (n=20)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Buntrock et al 2013</td>
<td>WSRs (blinded investigator): decrease between baseline (4.0) and week 2 (Belotero® 2.1 vs Perlane® 2.4), week 24 (2.4 and 2.7), and week 48 (2.7 and 2.8) (P&lt;0.001). No significant difference between treatments. WSRs (blinded rater): similar findings, WSRS still lower at week 48 (Belotero® P&lt;0.001; Perlane® P=0.046)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RCT split-face NLF</td>
<td>Patient WSRs: similar results, except significant difference between treatments at week 2 (WSRS –49% with Belotero® vs –36% with Perlane®, P=0.01). Reduction in wrinkle depth at 2, 24, and 48 weeks with both fillers (P&lt;0.05) – trend favorable to Belotero®. Depth reduction at 2, 24, and 48 weeks: Belotero® –98.1 (36%), –76.9 (28%), and –57.8 µm (21%); Perlane® –69.4 (31%), –44.1 (20%), and –37.2 µm (17%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Study design other than RCT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pavicic et al 2013</td>
<td>Belotero® Basic and Belotero® Intense combined (n=2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Case series</td>
<td>Case 1: at 30 months, no facial lipoatrophy and no NLF visible (just lines)</td>
<td>Case 1: mild erythema but no edema, hematoma, or other AEs after first injection</td>
<td>Case 1: not reported</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Study, design, and indication</th>
<th>Treatments and performance</th>
<th>Pain, safety, and tolerability</th>
<th>Investigator's and patient's satisfaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV-associated facial lipoatrophy</td>
<td>Case 2: 1 month after first injection, lipoatrophy at grade 0–1; 8 months later, loss of filling effect – second injection, 10 days later lipoatrophy grade 1; at 20 months, lipoatrophy grade 2–3 – third injection; at 26 months, lipoatrophy at grade 0</td>
<td>Case 2: no AEs after the first injection, injection-site erythema after the second injection (resolved within 1 day). In both cases, no difference between the two fillers regarding pain and other AEs</td>
<td>Case 2: fully satisfied 1 month after first injection and 10 days after second injection</td>
</tr>
<tr>
<td>Micheels*</td>
<td>Belotero® Intense alone (n=10)</td>
<td>Erythema and mild edema (n=1), translucent cord (n=1), overcorrection in the lip (n=1), slightly asymmetrical injection with a mild edema (n=1)</td>
<td>Two patients were not satisfied: injected volume too large in the lip (1.5 mL), injection slightly asymmetrical</td>
</tr>
<tr>
<td>Facial treatments</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Observational study (+ histology)</td>
<td>At 6 months, clinical improvement for all treated areas (not quantified)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pavicic28</td>
<td>Belotero® Intense alone (n=110) or combined with Belotero® Basic (sandwich procedure, n=2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Facial treatments (mostly NLF [84%])</td>
<td>WSRs improved after injection (3.98–2.28, P&lt;0.0001), with no decline over 12 weeks</td>
<td>Injection-site pain was mild (mean score of 2.7 on VAS). Post-injection AEs in 85.9% of patients, mostly related to injection procedure</td>
<td>Esthetic outcomes rated by physician as good/excellent in 83.3% of patients at 12 weeks. After injection, excellent/good satisfaction in 94% of patients and 90.6% of investigators (nearly maintained over 12 weeks)</td>
</tr>
<tr>
<td>Micheels et al65</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Open-label study</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Belotero® Volume</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study design other than RCTs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Micheels et al*</td>
<td>Belotero® Volume (n=56)</td>
<td>Only injection-site AEs</td>
<td></td>
</tr>
<tr>
<td>Observational study</td>
<td>FVLS scores improved from moderate at baseline to mild at 6 months with improvements of 53%, 57%, and 74% for the cheeks (3.5–1.6), cheek bones (3.8–1.6), and tear trough (3.8–1.0), respectively</td>
<td>On day 1, AEs in 14 patients (25%): swelling n=5, bruising n=3, redness n=2, pain n=2, induration n=2. At month 1, AEs in five patients (8.9%): swelling n=4, induration n=1 At month 3, AEs in five patients (8.9%): swelling n=3, induration n=1, discoloration n=1</td>
<td>All investigators reported that the volumizing effect was similar to (50%) or better than (50%) other volumizers. Injections rated as easy/very easy (50%) or equivalent to other products (40%)</td>
</tr>
<tr>
<td>Facial volume loss (mostly cheeks [38.6%], cheekbones [18.1%], and tear trough [18.1%])</td>
<td>GAIS by investigator: improvement at 6 months for all indications, more particularly for the cheeks (1.3) and tear trough (1.75). Cheekbones also responded well (2.0) GAIS by patients: “improved” to “very much improved”, from day 1 to 6 months</td>
<td>All mild except pain on day 1, one case of swelling at month 1, and discoloration at month 3 (all moderate)</td>
<td></td>
</tr>
<tr>
<td>Becker et al21</td>
<td>Modélis® Shape (n=10)</td>
<td></td>
<td>Patient's satisfaction (QoL from 0 to 100): baseline 68.0±24.0, 12 months 83.5±7.4 (+15.5%, P=0.04)</td>
</tr>
<tr>
<td>Observational study</td>
<td>MRI: HA volume +331% at 1 month (P&lt;0.0001), with no reduction at 12 months; skin thickness and tissue vascularization increased during the first 6 months. GAIS: very much improved n=2, much improved n=5, improved n=3</td>
<td>Slight erythema after injection n=2 (resolved in 2–3 days)</td>
<td></td>
</tr>
<tr>
<td>HIV-associated facial lipoatrophy</td>
<td></td>
<td>No skin hyperpigmentation, no pain, no itching</td>
<td></td>
</tr>
<tr>
<td>Facial treatments</td>
<td></td>
<td>No swelling, discomfort, or induration after injection</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>No allergic reaction, no product-related complications</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mild or moderate injection-site reaction (n=13 out of 20, 65%) Most frequent AEs on day 1: redness (n=5, 25%), pain (n=6, 30%), edema (n=3, 15%) Also transient bruising (n=1, 5%) and itching (n=1, 5%). Firmness (n=5, 25%), which resolved within 3 months</td>
<td></td>
</tr>
<tr>
<td>Micheels et al*</td>
<td>Modélis® Shape/Belotero® Volume (n=20, with eleven completers at month 18)</td>
<td></td>
<td>At month 12, 95% of patients were satisfied (ie, would repeat treatment)</td>
</tr>
<tr>
<td>Post-marketing clinical follow-up</td>
<td>Investigator’s FVLS score mean 3.1 at baseline, 1.3 immediately after injection, 1.3–1.8 between month 1 and month 18 (P&lt;0.0001) Investigator’s GAIS: immediately after injection and up to month 6, ≥94% of patients rated as very much/much improved; ≥65% from months 9 to 18 Patient’s GAIS: corresponding % were ≥83% immediately after injection up to month 6, and ≥50% from months 9 to 18</td>
<td>At month 18, 100% of patients (11/11) satisfied</td>
<td></td>
</tr>
<tr>
<td>Age-related mid face atrophy</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: aStudies with the same superscript letter were conducted in the same patients (eg, RCT and extension study). “Not formally assessed” means the outcomes are mentioned in the publication but without supportive numerical data.

Abbreviations: AEs, adverse events; FVLS, Facial Volume Loss Scale; GAIS, Global Aesthetic Improvement Scale; HA, hyaluronic acid; MRI, magnetic resonance imaging; NLF, nasolabial fold; ns, not significant; QoL, quality of life; RCT, randomized controlled trial; SAEs, serious adverse events; VAS, visual analog scale; WSRs, Wrinkle Severity Rating Scale.
Safety and efficacy of Belotero® fillers: a review

Basic/Balance and collagen. The average time (± standard deviation) between injections during the extension study was 37.0±15.6 weeks with Belotero® Basic/Balance and 30.9±13.6 weeks with collagen. Based on these data, the effects of Belotero® Basic/Balance treatment of NLFs seem to persist for 8–12 months.

In a large-scale uncontrolled prospective study conducted in 114 patients who underwent NLF filling, treatment success was obtained in 100% of patients after injection, 91% at 12 weeks, and 81% at 24 weeks (Table 4). Treatment success was defined as an improvement on the WRSS of 1 point or more, which was considered clinically relevant.

These positive findings, which were obtained in a majority of Caucasian patients with Fitzpatrick skin type II or III, were confirmed in patients with Fitzpatrick skin types IV, V, and VI (n=93), also for the filling of NLFs (Table 4).

Other skin areas/indications

In 49 patients who had injection of Belotero® Basic/Balance in the infraorbital hollow, an improvement in hollowness of at least 1 point was observed in 76.1% of patients at 2 months, an improvement which was maintained in 87% (27 out of 31) of patients at 10 months. In 40 patients who were injected Belotero® Basic/Balance in the tear trough, the average improvement in fold severity at 2–3 weeks was 1 point, and the average treatment longevity was 10.1±2.4 months.

Both studies indicate that the injection of Belotero® Basic/Balance in facial folds other than NLFs leads to a short-term improvement in fold severity of at least 1 point in the majority of patients, and that treatment longevity approximates at least 10 months, which is relatively similar to what was reported for NLF treatment.

The results of the study on atrophic scars are discussed in the “Belotero® Soft” section. The other studies where Belotero® Basic/Balance was investigated were focused on the safety of the product, the reduction of pain by the addition of lidocaine, or did not formally assess the performance of the filler.

Tolerability and safety of Belotero® Basic/Balance

Pain

In the 4-week RCT, pain recorded immediately after injection was lower with Belotero® Basic/Balance than with Restylane® (both being lidocaine-free). Both treatments scored slightly over 6 on the 11-point scale (Table 3), without a statistically significant difference between treatments.

To further decrease the pain experienced during and immediately after injection, lidocaine was recently added to Belotero® Basic/Balance (April 2014). Significant pain relief was demonstrated in a split-face trial, with pain intensity going from 5.8±2.1 without lidocaine to 2.8±1.1 with lidocaine, on the 11-point scale (P=0.0001). Milder and nonstatistically significant benefits were observed in a parallel-group trial, with mean pain scores (on each side of the face) following injection slightly lower with lidocaine (3.6–3.8 without epinephrine, 3.6–4.6 with epinephrine) than without lidocaine (4.5–5.3).

Figure 2. Change in nasolabial fold severity with Belotero® Basic/Balance treatment, re-treatment, and optional touch-ups.

Notes: In Prager et al’s study, fold severity was rated using the Merz Aesthetics Scales at baseline and at 1, 6, 9, and 12 months. In Narins et al’s study, fold severity was rated using the Wrinkle Severity Rating Scale at baseline and at 24, 32, 48, 72, and 96 weeks. Baseline is before the injection. Data from Narins et al, and Prager et al.

Abbreviation: t-u, touch-up allowed.
Adverse events
The majority of adverse events (AEs) related to Belotero® treatment (ie, product or injection procedure) are injection-site AEs of mild or moderate intensity.36

Based on the studies with a large sample size (>90 patients), the percentage of patients reporting related AEs with Belotero® ranged from 61% (70 out of 114)33 to 77.4% (72 out of 93).34

The most frequently reported injection-site AEs were erythema/redness,9,33,34,36–41 edema/swelling,33,34,36–41 and hematoma/bruising9,34,36–41 with an incidence ranging from 2.5% up to >50% (Table 2). Other common injection-site AEs included induration, discoloration, nodule, pruritus, and pain.

Injection-site AEs are generally of short duration, the majority resolving in no more than 7 days.34,36,38,39 More rarely, these AEs last for 2–3 weeks41 or several months.40 They tend to occur shortly after injection, although cases of delayed swelling (ie, 2 weeks after injection) have been reported.22,40 Bruising, nodules, swelling, and induration were the injection-site AEs that lasted longer than a week in >10% of the 118 patients enrolled in the 6-month RCT.36

Regarding injection-site bruising, the addition of epinephrine (as a vasoconstrictor agent) to Belotero® Basic/Balance containing lidocaine did not reduce bruising.31

Severe AEs have been reported relatively rarely (Table 4). In the 6-month RCT (n=118), the severe AEs considered related to the procedure with Belotero® were swelling (6.8%) and bruising (8.5%).36 Of the severe AEs considered related to Belotero® itself, injection-site nodule was the only event reported in >5% of patients (5.9%).36 A severe AE of pain has also been reported (in one out of 40 patients treated with Belotero®).37

No treatment-related serious adverse events (SAEs) and no AEs leading to discontinuation have been reported in any of the reviewed papers presenting safety data on Belotero® Basic/Balance. There were no reports of persisting nodules, granulomas, or Tyndall effect.38

Belotero® was also found to be safe in Fitzpatrick skin types IV–VI (Table 4).34

No major differences in safety profiles were observed in head-to-head comparisons between Belotero® Basic/Balance and collagen,36 and other HA fillers (Restylane® or Juvederm®).9,37

Long-term tolerability
During the 2-year safety follow-up in 13 patients treated with either Belotero® Soft or Basic/Balance, no delayed AEs and no allergic reactions were reported.26

Repeated Belotero® injections over time were also well tolerated, with no inflammatory reactions or granulomas reported.26,35 In the open-label extension study on correction of NLFs, where repeat injections were given over an 18-month follow-up period, injection-site bruising was the only AE that was considered related to Belotero®.35 The measurement of HA antibodies revealed that 86.1% of patients (n=79) had no detectable anti-HA IgG antibodies and 100% had no anti-HA IgE antibodies.35 Only three patients had positive anti-HA titers, but only one of them showed an increase from pre- (<400 ng/mL) to posttreatment (3,487 ng/mL). The authors concluded that Belotero® has little potential for immunogenic reactions.35

As a comparison, a similar study had been done in 425 patients who received Restylane® and/or Perlane® (manufactured with NASHA®).43 All anti-NASHA® IgE tests were negative. Serologically, 91.8% (n=390) of patients were negative for anti-NASHA® IgG. One patient had a four-fold increase in anti-Restylane® IgG after injection but reported no AEs other than headache on the day after injection.43

Patients’ and investigators’ satisfaction with Belotero® Basic/Balance
In the 6-month RCT vs collagen, Belotero® Basic/Balance was preferred to collagen by ~80% of the patients (n=107) and five out of six investigators (in particular due to its storage, handling, and comfort and design of its syringe).36 The patients’ satisfaction rate was higher with Belotero® Basic/Balance (78.2%) than with collagen (65.1%, P<0.001).36

The results were more equivocal when comparing the patient’s satisfaction with different HA fillers at 4 weeks.37 In a two-arm split-face trial, approximately half the patients found both fillers acceptable or did not state a preference (13 out of 20 in Arm A, five out of 20 in Arm B). Among those who had a preference, five out of 20 (25%) patients preferred Belotero®, while two out of 20 (10%) preferred Restylane® in Arm A, and eight out of 20 (40%) preferred Belotero®, while seven out of 20 (35%) preferred Juvederm® Ultra 3 in Arm B (Table 4).

Belotero® Hydro
Belotero® Hydro, in contrast to the other Belotero® fillers, is a non-crosslinked product (Table 1). It is indicated for skin hydration, as well as improvement of skin elasticity and firmness. This product has been tested in one study for the rejuvenation of the periorbital area.44
Performance of Belotero® Hydro

After three monthly injections in the periorbital area, the three investigators and a blinded rater assessed the skin appearance (brightness, texture, and turgor) and rated the improvement using a discrete scale (100%, 90%, 75%, 50%, or 25% improvement, no improvement, or worsening of the skin). In general, the investigators’ ratings ranged from 25% to 50% improvement, while the independent rater considered that more than half the patients showed a 50% improvement. None of the patients had a worsening of the skin appearance.44

Tolerability and safety of Belotero® Hydro

Pain

Approximately 80% of patients reported mild tolerable pain during injection, with only one case of severe pain.44 Injection was performed in the superficial dermis with a 30 G needle, using the micropuncture technique (Table 2).

Adverse events

Reported AEs were injection-site AEs, most frequently medium-sized papules, edema, and hematoma (in >70% of patients), and less frequently erythema (in ≤30% of patients), all of which resolved within 7 days. There were no SAEs.

Patients’ and investigators’ satisfaction with Belotero® Hydro

Two weeks after the third injection (ie, at 2.5 months), the mean score given to Belotero® Hydro by the patients was 5.9, on a scale from 0 (worst result) to 10 (best result).44

Belotero® Soft

Belotero® Soft has been tested in four studies, either for facial treatments26,27,30 or for treatment of atrophic scars.25 Following the first pilot study conducted on Belotero® Soft,27 a 24-month safety follow-up has been published.26 In all these studies, other Belotero® dermal fillers were tested (Basic/Balance,25-27 whole Belotero® range30), and the results of Belotero® Soft were pooled with those of other fillers (Table 2).

Performance of Belotero® Soft

In the pilot study27 and its 24-month safety follow-up26 where patients received facial treatments, the performance of Belotero® Soft was not formally assessed (Table 4).

In the 12 patients treated for atrophic scars with either Belotero® Soft or Belotero® Basic/Balance, the esthetic improvement was rated as good or excellent by 74% of investigators and 100% of patients, 1 week and 1 month after injection (Table 4).25

In the three patients who underwent facial rejuvenation with a sequential approach (botulinum toxin followed by calcium hydroxyapatite a month later and HA filler 2 or 4 weeks later), fold severity improved at almost all treated sites 11–14 days after the last treatment. The injection of Belotero® (last treatment in the sequential approach) led to further improvement in the esthetic outcomes in six out of eleven treated sites in all three patients.80

Tolerability and safety of Belotero® Soft

Pain

Pain during injection was rated as mild or moderate by the patients treated for atrophic scars.25

Adverse events

No study reported the exact count of AEs with Belotero® Soft. Mild erythema immediately after injection has been reported in the study on atrophic scars; however, the event resolved spontaneously within a few hours.25 In the 2-year safety follow-up26 of the pilot study,27 rare bruises have been reported with the 30 G needle, along with short-lasting erythema (resolving within 24 hours, also reported by Hasson and Romero25) and very light swelling immediately after injection. Based on these findings, Belotero® Soft may be injected safely with predictable results in easily swollen and thin skin areas such as the periorbital area (Figure 3). Importantly, no allergic reactions and no granulomas have been reported during the 2-year follow-up. Altogether, these findings suggest that the reactions to Belotero® Soft were related to the injection procedure rather than the product itself.

Figure 3 Esthetic effect of Belotero® Soft.

Notes: A 30-year-old female patient with congenital unilateral (left) upper eyelid hollowness received 0.2 mL of Belotero® Soft in the suborbicularis fibroadipose tissue (pre-septal) layer using a blunt tip cannula to prevent bruising and intravascular injection. The product was spread as a thin layer to avoid swelling and lumps. Photo courtesy of AD Prasetyo.
Patients' and investigators' satisfaction with Belotero® Soft

Following the first sessions of treatment with either Belotero® Soft or Belotero® Basic/Balance, most of the 13 patients who participated in the safety follow-up had further treatments performed during the 2 following years (on the same area or other areas), suggesting a general satisfaction with the procedure.

Belotero® Intense

Among the five studies that investigated the use of Belotero® Intense, one was focused on NLFs (the only RCT), two on various facial treatments of deep lines and wrinkles, one on two cases of HIV-associated facial lipoatrophy, and one on whole-face rejuvenation using a combination of fillers.

Performance of Belotero® Intense

One RCT using a split-face design has been conducted on Belotero® Intense, with the HA filler Perlane® as a comparator (n=20), to treat NLF rated as moderate to severe at baseline.

In this 48-week trial, the mean reduction in wrinkle depth at 2, 24, and 48 weeks was significant with both treatments (P<0.05) and was greater (although not statistically significantly) with Belotero® Intense (−98.1, −76.9, and −57.8 µm, respectively) than with Perlane® (−69.4, −44.1, and −37.2 µm, respectively), as assessed by skin topography (phase-shift rapid in vivo measurement of skin).

The difference between treatments reached statistical significance when considering the reduction in WSRS at 2 weeks, when assessed by the patient (−49% with Belotero® Intense vs −36% with Perlane®, P=0.01). The reduction in WSRS scores was also significant at 24 and 48 weeks, for both fillers (P<0.001).

In a large open-label study (n=149), Belotero® Intense has been tested, either on its own or after injection of Belotero® Basic/Balance. In the second case, the procedure is referred to as the “sandwich technique”, which generally describes injections performed in two different depths or more (superficial-to-deep dermal injection). The assessment of WSRS post-injection, at 2 and 12 weeks confirms the findings of the 48-week RCT. The WSRS score was significantly reduced at all time points (P<0.001), with the lowest value obtained at 2 weeks. The combined results of both studies are presented in Figure 4.

The maintenance of the treatment effect over 12 weeks was confirmed by the investigator’s GAIS ratings, with 59.7% and 57.0% of patients considered as much/very much improved at 2 and 12 weeks, respectively. The esthetic effect of the filler was rated as good or excellent in 83.3% of patients.

Regarding treatment longevity, mean wrinkle depth and WSRS scores were still lower, and the patient’s satisfaction was still higher, up to 48 weeks (11 months) after injection (P<0.001, Figure 4). A 1-year follow-up study in 28 patients treated on different facial areas also indicated that the esthetic effect of Belotero® Intense remained clinically relevant for 9–12 months.

Figure 4: Long-term change in nasolabial fold severity with Belotero® Intense treatment based on the investigators’ rating on the Wrinkle Severity Rating Scale.

Notes: The difference from baseline was statistically significant at each time point, in both studies (P<0.001). The mean trend shows the average scores when pooling data from the two studies. In Buntrock et al’s study,19 the ratings were performed by a blinded investigator at baseline (ie, before injection) and at 2, 24, and 48 weeks. In Pavicic’s study,28 the ratings were performed by an unblinded investigator at baseline, immediately post-injection, and then at 2 and 12 weeks. In both studies, touch-ups were not allowed. Data from Buntrock et al.19 Adapated from Pavicic T. Efficacy and tolerability of a new monophasic, double-crosslinked hyaluronic acid filler for correction of deep lines and wrinkles. J Drugs Dermatol. 2011;10(2):134–139.9

Abbreviation: WSRS, Wrinkle Severity Rating Scale.
Other skin areas/indications
Two patients with HIV-associated facial lipoatrophy were treated with a combination of Belotero® Basic/Balance and Belotero® Intense. Patients were satisfied with the results; however, they had to undergo injections every 6–12 months to maintain the esthetic outcomes.

Tolerability and safety of Belotero® Intense

Pain
In the 48-week split-face RCT, pain after injection was lower with Belotero® Intense than Perlane® (3.9 vs 5.0, \(P=0.01\)), which were both lidocaine-free. In two patients treated for facial lipoatrophy, pain was reported to be similar between Belotero® Basic/Balance and Belotero® Intense.

Adverse events
Similar to what was reported with Belotero® Basic/Balance, the majority of the events related to Belotero® Intense treatment were injection-site AEs of mild or moderate intensity.

In the open-label study including 149 patients, 39 of whom received Belotero® Basic/Balance after Belotero® Intense, 85.9% of patients reported AEs immediately after injection, most of which were related to the procedure. This incidence dropped to 12.8% at 2 weeks and 3.4% at 12 weeks, illustrating the short-term nature of these events.

Most common AEs were erythema, edema, pain, bruising (which could be severe), and induration, with a reported incidence ranging from 21.5% to 63.8%. Mild–to-moderate tenderness, nodules, and pruritus have also been reported.

No induration, nodules, or granulomas were observed in the two patients treated for HIV-associated facial lipoatrophy.

Long-term tolerability
Long-term clinical data regarding the tolerability of Belotero® Intense are currently lacking. In the split-face RCT, both Belotero® Intense and Perlane® were well tolerated during the 12 months following a single injection. In the large-scale open-label study, tolerability was rated as poor in only one case (0.7%) and was considered as excellent or good at 3 months in 96.6% of cases.

Patients’ and investigators’ satisfaction with Belotero® Intense
The positive findings regarding the performance (mean wrinkle depth and WSRS) and safety of Belotero® Intense in the 48-week RCT were confirmed by the patient’s satisfaction rate. A higher percentage of patients were satisfied with Belotero® Intense than Perlane® at 24 (62% vs 51%, \(P=0.002\)) and 48 weeks (43% vs 33%, \(P=0.005\)). For Belotero® Intense, the patient’s satisfaction at 48 weeks was still higher than at baseline before injection (43% vs 29%), whereas satisfaction came back to baseline value with Perlane® (33% vs 31%). In accordance with these findings, 80% of patients would repeat their treatment with Belotero® Intense, vs 65% of patients with Perlane®.

Short-term satisfaction rates were even higher. In the 12-week open-label study, the large majority of investigators and patients (90.6% and 94%) rated their satisfaction as excellent or good. In particular, mean investigators’ ratings of syringe handling, injection pressure, filler dispersal, and plasticity ranged from 1.50 to 1.88 (1 being excellent, 2 being good).

Belotero® Volume
Belotero® Volume has been used for treating facial lipoatrophy, associated with either HIV or age, or more generally facial soft-tissue volume loss.

Performance of Belotero® Volume
In patients with HIV-associated lipoatrophy (n=10), the performance of Belotero® Volume has been objectively assessed using MRI. One month after injection, the volume of the filler had increased by 331% on average (\(P<0.0001\)), and no volume reduction was observed at 12 months. Skin thickness and tissue vascularization also increased during the first 6 months of the study (\(P=0.01\)).

Injection of Belotero® Volume in 20 patients with aged-related mid face lipoatrophy and 56 patients with facial volume loss led to a marked decrease in the severity of volume loss, which persisted for at least 6 months and for up to 18 months (Figure 5 presents results in the cheeks).

According to GAIS scores, all patients considered themselves, or were considered by the investigators, as “improved” to “very much improved” at 6 months, and even 12 months (Table 4).

Tolerability and safety of Belotero® Volume

Pain
Pain of mild-to-moderate intensity was reported immediately after injection in six out of 20 patients (30%) treated with Belotero® Volume.

Adverse events
Mild-to-moderate injection-site AEs were the most common AEs reported with Belotero® Volume, with an incidence of 20% (two out of 10 patients), 25% (14 out of 56 patients), 47%
or up to 65% (13 out 20 patients). The most common AEs after injection were erythema, pain, and edema. Edema persisted for up to 3 months in four cases overall. Of these four cases, one patient experienced persistent edema in the orbital margin (following injection of 1.9 mL of product on both sides), which was successfully treated with a hyaluronidase injection. According to the authors, this event could have been caused by inaccurate injection (too close to the orbital margin), inaccurate remodeling (moving the product too close to the orbital margin), and lymphatic spread or reactive edema. Cases of transient bruising, itching, and induration have also been reported. Patients’ and investigators’ satisfaction with Belotero® Volume

In accordance with the MRI findings obtained in ten patients with HIV-associated lipoatrophy, patient’s satisfaction significantly improved between baseline and 12 months (+15.5%, P=0.04). The level of satisfaction was excellent in patients treated for age-related facial lipoatrophy, with 95% (19 out of 20) and 100% (eleven out of eleven) of patients being satisfied 12 and 18 months after injection. In addition, the investigators reported that the volumizing effect was instantaneous and similar to (50%) or better than (50%) other volumizers such as Juvederm® Voluma, Restylane® SubQ, Radiesse®, and Teosyal® Deep.

Discussion

The clinical data on the Belotero® dermal fillers were reviewed to analyze the performance, tolerability, and safety of these fillers for soft-tissue augmentation and rejuvenation. The best level of evidence concerns the performance of Belotero® Basic/Balance, which has been compared to collagen and to other HA fillers in the treatment of NLFs, in split-face RCTs. Belotero® Basic/Balance was found to be superior to collagen and to result in a greater reduction of wrinkle depth than Restylane® 4 weeks after injection. At 12 months, esthetic results were relatively similar between HA fillers. The performance of Belotero® Basic/Balance, which was demonstrated in Caucasian patients in the treatment of NLFs, was confirmed in patients with Fitzpatrick skin types IV, V, and VI and in the treatment of infraorbital hollow and tear trough. An improvement of at least 1 point on the severity scale, which is considered as a clinically relevant outcome, can be expected in ~80% of patients, 1–6 months after injection, and persistence of treatment effect for 8–12 months.

Belotero® Intense was also found to be successful in facial treatments, with good level of evidence obtained for NLF filling. When compared to Perlane®, patient’s satisfaction was higher with Belotero® Intense, possibly due to the slightly better esthetic results and lower pain. Regarding Belotero® Volume, a convincing MRI study on the treatment of HIV-associated facial lipoatrophy showed no...
reduction in the volume of HA at 12 months,\textsuperscript{21} and investigations to further support this filler are ongoing. Further clinical studies are needed to assess the performance of Belotero\textsuperscript{®} Hydro and Soft. In the case of Belotero\textsuperscript{®} Volume and Hydro, the lack of published clinical evidence can be explained by the later introduction of these products on the market compared to Belotero\textsuperscript{®} Basic/Balance.

Regardless of the type of Belotero\textsuperscript{®} dermal filler, the most common adverse effects noticed were mild-to-moderate erythema, edema, and hematoma, most of which resolved within a few days or weeks and were related to the injection procedure rather than the filler itself. No persisting nodules, granulomas, and tissue necrosis due to intravascular injection have been reported in long-term safety reports.\textsuperscript{26,35,38} When injected into the abdominal skin, Belotero\textsuperscript{®} products (Basic/Balance and Intense) were found to induce the least immunological reaction compared to other fillers (biphasic fillers, monodensified monophasic fillers, or collagen).\textsuperscript{48} Altogether, these findings suggest a good long-term tolerability of these fillers.\textsuperscript{10}

HA is increasingly used for esthetic purposes due to its excellent water-binding capacity.\textsuperscript{49} With a dry weight of 5.5 mg/mL,\textsuperscript{49} its filling capacity is higher than the one of collagen (dry weight 65 g/mL), the latter no longer playing a role in clinical practice. However, differences exist between HA fillers regarding their viscoelastic properties (cohesivity, elasticity, viscosity, and plasticity), which describe how the filler deforms, flows, and behaves.\textsuperscript{50} Since the natural elasticity or tension of the skin tends to deform and flatten out the implant,\textsuperscript{50} the viscoelastic properties determine the clinical effects of the filler.\textsuperscript{5,11,50}

Belotero\textsuperscript{®} dermal fillers present with a unique balance between elasticity and viscosity, which correlates with the soft, flowing qualities of these fillers.\textsuperscript{17,51} When compared to other fillers such as Restylane\textsuperscript{®}, Juvéderm\textsuperscript{®} Ultra 3/Ultra 4/Volma, or Teosyal\textsuperscript{®} Deep Line/Deep, the Belotero\textsuperscript{®} fillers provide a “smoother” esthetic effect.\textsuperscript{17,51}

This effect is due to the homogeneous tissue distribution of the filler intradermally, as demonstrated on ultrasound images\textsuperscript{22–24} and by histology.\textsuperscript{11,12,23,24,48} When injected into the middle layer of the reticular dermis, Belotero\textsuperscript{®} Basic/Balance (monophasic polydensified gel) distributes uniformly throughout the reticular dermis, filling the spaces between collagen bundles.\textsuperscript{12} In contrast, Restylane\textsuperscript{®} (biphasic gel) showed large pools of HA in the mid dermis and subcutaneous tissue, while Juvéderm\textsuperscript{®} Ultra 3 (monodensified monophasic gel) remained within the dermis but retained aggregation characteristics.\textsuperscript{12} Scanning electron microscopy was used to study the localization and ultrastructure of the HA polymers in dermal fillers.\textsuperscript{52} The HA polymers appeared as a fibrous network structure suspended in an aqueous medium. Belotero\textsuperscript{®} Balance presented as the filler with the most uniform distribution, followed by Juvéderm\textsuperscript{®} Ultra and Restylane\textsuperscript{®}. Whereas no discrete particles could be detected in Belotero\textsuperscript{®} Balance and Juvéderm\textsuperscript{®} Ultra, Restylane\textsuperscript{®} showed particles of irregular size embedded in a diffuse network.\textsuperscript{52}

The viscoelastic properties of Belotero\textsuperscript{®} Basic/Balance allow injecting the filler into the superficial layer of the reticular dermis, by using the “blanching technique” without producing any Tyndall effect.\textsuperscript{24} This technique is characterized by the temporary blanching of the injected area (for ~10 minutes), due to the transparent appearance of the gel as a result of its proximity to the skin surface.\textsuperscript{24} A very close multipuncture approach is required, with a 30 G needle or finer, rather than the conventional retrograde approach used for HA fillers injected in the mid and deep dermis. Homogeneous tissue integration of HA, along with mild-to-no inflammation, was seen after injection of small volume of Belotero\textsuperscript{®} Basic/Balance (0.2 mL) using this technique.\textsuperscript{23,24} Thanks to the small volume of filler injected per wrinkle, many areas can be treated with high effectiveness, high patient satisfaction, and little-to-no risk of Tyndall effects.\textsuperscript{24}

Another distinct feature of the Belotero\textsuperscript{®} dermal fillers is the presence of high-density and low-density zones in the gel, as a result of the CPM\textsuperscript{®} technology.\textsuperscript{16} Similar to Restylane\textsuperscript{®}, Perlane\textsuperscript{®}, and the Juvéderm\textsuperscript{®} range of products, the HA in Belotero\textsuperscript{®} dermal fillers is crosslinked using 1,4-butenediol diglycidyl ether. However, the Belotero\textsuperscript{®} products differ from most other HA fillers by the addition of another crosslinking step which stretches the matrix obtained during the first step and adds more HA strands, thereby continuing the crosslinking process without the addition of further 1,4-butenediol diglycidyl ether. As a result, the matrix combines higher and lower crosslinking densities of HA. This characteristic allows the filling of deeper but also smaller, finer wrinkles,\textsuperscript{37} contributing to the homogeneous intradermal distribution of the material.\textsuperscript{3,11,53} In the meantime, the cohesivity of the matrix allows the gel to stay intact.

Clinical data indicate that treatment longevity is similar between HA fillers, with similar fold severity scores obtained with Belotero\textsuperscript{®} Basic/Balance, Restylane\textsuperscript{®}, and Juvéderm\textsuperscript{®} Ultra 3 at 12 months (1.5–1.6),\textsuperscript{37} and with Belotero\textsuperscript{®} Intense and Perlane\textsuperscript{®} at 48 weeks (ie, 11 months; 2.7–2.8).\textsuperscript{19} These findings are reinforced by in vitro investigations, showing that Belotero\textsuperscript{®} is similarly\textsuperscript{16} or less懂 degraded by hyaluronidase...
than other HA fillers. The clinical outcomes at 6, 12, or 18 months are more meaningful, since short-term outcomes at 2–4 weeks may be confounded by the edema and bruising caused by the procedure.

The viscoelastic properties of the fillers affect not only the performance and longevity of treatment but also the tolerability and safety of the products. The viscoelastic properties of Belotero® dermal fillers allow for a low and even injection pressure, which is thought to decrease pain and other AEs.49 However, pain during and immediately after injection remains a common side effect of any HA filler. To address this issue, the Belotero® dermal fillers – except Belotero® Hydro – now come with or without lidocaine. In a split-face trial in 29 patients, the addition of lidocaine led to a 3-point decrease in the average pain score, on a 10-point scale.32 Of note, the density of nociceptors is higher in the upper dermis compared to the deeper dermis, which could explain the pain that patients tend to experience with the blanching technique.32

In general terms, Belotero® dermal fillers showed a safety profile that was slightly better than collagen46 and relatively similar to other HA fillers tested in split-face RCTs.9,19,37

The adverse effects reported with Belotero® dermal fillers are those commonly seen with other fillers (erythema, edema, ecchymosis).38 Bruising tends to be more common when treating areas with a high density on blood vessels. Despite being considered as a potential side effect,27 no Tyndall effect has been reported with Belotero® dermal fillers, including in the large-scale studies (>90 patients).28,33,35–37,39 The use of hyaluronidase to treat an AE was reported in only one patient treated with Belotero® Volume and who experienced persistent edema in the orbital margin.46 This event could have been caused by inaccurate injection, inaccurate remodeling, or lymphatic spread.

The relatively high incidence of nodules reported by Narins et al in their 6-month RCT (33.1% of patients vs 55.1% with collagen; Table 4)36 contrasts with the absence of nodules after re-treatment and touch-ups during the 2-year follow-up,55 and the absence of nodules in the majority of published studies. Reasons for these findings are unclear. They may be due to the inconsistent definition of nodules and granulomas in the literature,55 or to different injection techniques, since nodules are frequently caused by an incorrect technique.

Repeated injections of Belotero® dermal fillers seem to be well tolerated.26,29,35,40,44 These findings are consistent with the measurement of HA antibodies, suggesting little potential for immunogenic reactions following Belotero® injection,35 and with histological findings.11,23,24,48 When injected into the abdominal skin, Belotero® products (Basic/Balance and Intense) induced a histomorphological reaction free of inflammation, whereas other dermal fillers (Restylane®, Perlane®, Juvederm® Ultra 3 and 30 HV, Surgiderm® 24 XP and 30, Teosyal® Global Action and Deep Lines) provoked varying, predominantly slight-to-moderate degrees of chronic inflammation.48 Nevertheless, these data were collected over a 30-day period. Long-term tolerability data, especially regarding the risk of delayed immune-related AEs,56,57 are therefore needed.

The practitioners showed high levels of satisfaction with Belotero® Basic/Balance,36 Intense,28 and Volume,46 in particular regarding the ease of use of these fillers.28,36 Similarly, the patients’ satisfaction rate with the different Belotero® dermal fillers ranged from 60% to 94%,19,28,36,46 with a majority of patients returning for further treatments.26,38 These satisfaction rates are likely explained by the esthetic effects of the fillers combined with their good tolerability.

Clinical evidence indicates sustainable esthetic effects, good safety profile, and long-term tolerability of the Belotero® dermal fillers, with the best level of evidence supporting Belotero® Basic/Balance and Intense. Treatment effects are immediate and last for ~6–12 months, depending on the filler. Patient’s satisfaction was shown to be high across fillers, which could be explained by the excellent tissue integration of the material combined with a good safety profile and reasonable level of pain during and immediately after injection. There were no reports of SAEs related to the product or the injection procedure, and no reports of Tyndall effect. Belotero® Basic/Balance and Soft offer the possibility of injecting in the superficial layer of the dermis using the blanching technique. More studies would be needed on the Belotero® dermal fillers more recently introduced on the market.

Acknowledgments
Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany, provided financial support for the manuscript preparation and gratefully acknowledges Scinopsis Medical Writing for their assistance. None of the authors received any financial support for the writing of this manuscript. Written patient consent was obtained for the use of the photos in Figure 3.

Disclosure
Dr Prasetyo is a consultant and sits on advisory boards for Allergan and Merz Pharmaceuticals, and has received grants, honoraria, and travel support for giving lectures from
Allergan, GlaxoSmithKline, Merck Sharp & Dohme, and Merz Pharmaceuticals. Dr Prager is a lecturer and researcher for Allergan, Beiersdorf, Cynosure, Galderma, Lumenis, Merz Pharmaceuticals, and Skinceuticals. Dr Rubin is a consultant for Merz Pharmaceuticals. Dr Nikolis is a consultant and speaker for Allergan, Galderma, and Merz Pharmaceuticals. Dr Moretti has no conflicts of interest to declare in this work.

References


